In STEMI group, complications were common, more in patients with recurrent chest pain and evidence of ECG changes as compared to those without ECG changes i.e. 16% and 10% respectively. Mortality was also higher (10.5%) in patients of recurrent chest pain and ECG changes compared to those without ECG changes (6.8%). Among 140 patients of NSTEMI, 48 (34.28%) had recurrent chest pain; 30(62.5%) with ECG changes and remaining 18(37.5%) without ECG changes. CONCLUSION: In NSTEMI and STEMI patients, recurrent chest pain and ECG changes are bad prognostic markers as compared to recurrent chest pain without ECG changes. These patients are more likely to suffer complications and can benefit from aggressive/invasive strategy than patients with recurrent chest pain without ECG changes. In NSTEMI group, complications and mortality are more frequent in patients with recurrent chest pain and ECG changes compared to those without ECG changes.
INTRODUCTION
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the world. 1 There is a high incidence of CAD in South Asia at an earlier age compared to other populations especially in the Western world. 2, 3 In Pakistan, in particular, its documented manifestations have been steadily increasing since early sixties. [4] [5] [6] The manifestations of CAD include chronic stable angina, acute coronary syndrome (ACS), congestive heart failure, sudden cardiac death and silent ischaemia. ACS encompasses a spectrum of clinical conditions; from unstable angina to ST elevated myocardial infarction (STEMI) and non-ST elevated myocardial infarction (NSTEMI). The acute event usually represents a rupture of vulnerable atherosclerotic plaque, and platelet aggregation of varying degrees ensues, limiting blood flow to the myocardium distal to the lesion. The resulting supply demand mismatch can result in unstable angina, STEMI and NSTEMI. 7 The development of STEMI is a fatal event in approximately one third of patients with about half of deaths occurring within one hour of the event from ventricular arrhythmia. 8 The clinical diagnosis of MI requires an integrated assessment of the history with evidence of myocardial necrosis through biochemical markers, electro cardiographic and imaging modalities. Epidemiological reports from the World Health Organization and American Heart Association beginning in late 1950 required the presence of at least two of the following characteristic symptoms; ECG changes and a typical rise and fall in biochemical markers for the diagnosis of myocardial infarction. 1 Intravenous thrombolytic therapy has led to a dramatic improvement in the outlook for patients with acute MI. However, reocclusion of the infarct-related artery occurs in some patients leading to increased morbidity and mortality. 9 Timely reperfusion of jeopardized myocardium represents the most effective way of restoring the balance between myocardial oxygen supply and demand. When fibrinolysis is administered, the extent of protection appears to be related directly to the rapidity with which reperfusion is implemented after onset of coronary occlusion. 10, 11 Patients with STEMI and NSTEMI may develop complications. Most of them have recurrent chest pains and require readmission or prolonged hospital stay. This study was carried out to compare the outcomes of acute STEMI with NSTEMI with special reference to recurrent chest pain and mortality. 
PATIENTS AND METHODS

This
Inclusion criteria:
Biochemical markers: Raised cardiac enzymes like CPK + CKMB, SGOT and LDH within four hours of admission and other two sets 6 hours onward. Positive Trop-T, 4 to 6 hours after the onset of symptoms. The patients were selected on the basis of positive biomarkers as above and one of the following: Electrocardiography: Either ST elevation of more than 1mm in two consecutive leads or ST depression of more than 2mm in two consecutive leads. History: of chest pain of at least 30 minutes and within 48 hours. These patients were also put in two groups:
(1) STEMI: ST elevation of >1mm in 2 consecutive leads with positive bio-chemical markers.
(2) NSTEMI: ST depression of >2mm in 2 consecutive leads with positive bio-chemical markers.
Exclusion criteria:
• Those patients having MI of more than 48 hours.
• If another cause of chest pain was established e.g. pericarditis or pneumonia.
Main outcome measures of the study were recurrent symptoms and mortality in both STEMI and NSTEMI groups. The patient's cardiovascular history, their risk factors (smoking status, history of hypertension, hyperlipidaemia, family history, diabetes, their inhospital clinical course including recurrent chest pain, maximum Killip class, and the initial diagnostic and treatment management were recorded on a predesigned proforma for each patient. Data was analyzed through SPSS version 10.0 software program. Equipment used for study purpose was three channel electrocardiography machine (Toshiba and Fakuda).
RESULTS
During study period, total 580 patients were hospitalized with acute coronary syndrome. However, 428 patients were studied as per eligibility criteria. 12, 13 According to American Heart Association guidelines, patients with evidence of residual ischaemia (either by ECG, biomarker, or LV dysfunction) need early invasive treatment as there is upto 45% reduction of adverse events and 18% reduction of mortality due to it. 14 In this study, patients of STEMI group having recurrent chest pain with evidence of ECG changes were more likely to develop adverse events (i.e.16%). Their mortality was also higher (11.5%). In other words, ECG changes with chest pain predicted the trouble. Those patients with STEMI and recurrent chest pain but without ECG changes were less likely to suffer adverse events i.e. 10% and mortality of only 6.8%. These patients need early conservative strategy and their pain should be evaluated on non-invasive workup. There is little data, comparing outcome of patients with STEMI and recurrent chest pain without residual ischaemia. GUSTO II study suggests that patients with ST elevation have higher mortality than NSTEMI. 15 Although, ST depression had more adverse events, but in this study, overall adverse events in patients with STEMI were between 10% to 16% and mortality was 6.7% to 11%, which is higher as compared to various other world centers, in agreement with the world literature but lower than the patients of NSTEMI in contrast to the world literature. This could be explained on the basis of public awareness; patient seeking and getting attention earlier shorter door to [16] [17] [18] Available literature suggests that these patients shall be referred for early invasive strategy. 19, 20 In TIMI TACTIS 18 study, there was 18% to 22% reduction of mortality in this group. 21 However, in this study, it was found that not all recurrent chest pain patients were at high risk, but only those with evidence of ECG changes. Patients of NSTEMI who were without ischaemic evidence were having decreased adverse events and low mortality i.e. 11%. This study shows higher mortality in patients with NSTEMI (12.4%) as compared to available literature. 16, 18, 20 Patients with NSTEMI comprise a growing subgroup of patients with ACS, producing a major public health problem worldwide, especially in Western countries, despite, significant improvements and refinements in management over the past 20 years. In United States alone, over 2.4 million people suffer from ACS each year, with more than six million individuals undergoing in-hospital vascular and cardiac surgery and related procedures. 22 Consequently, much attention has been directed towards optimizing the diagnosis and management of such patients, particularly in light of the continued evolution of catheter-based interventions and newer pharmacologic strategies that afford more complete platelet and thrombin inhibition. When used together, these approaches appear to have an important synergistic effect in reducing prognostically important ischaemic events. 23, 24 Recently, compelling evidence from randomized clinical trials has demonstrated that intermediate and high-risk ACS patients derive significant reductions in both morbidity and mortality with mechanical or surgical intervention, especially when revascularization is coupled with aggressive, multifaceted (antiplatelet, antithrombin, anti-ischaemic and antiatherogenic) medical therapy. 20, 24 For these reasons, it seems especially timely and appropriate to undertake a comprehensive review of the latest advances in the management of NSTEMI, mindful of the fact that even this noble effort to synthesize and integrate a prodigious amount of scientific information and cardiovascular therapeutics is destined to evolve still further as intensive efforts on optimizing clinical outcomes by harmonizing the advances in mechanical and pharmacologic interventions continue unabated.
CONCLUSION
This study concludes that STEMI/NSTEMI patients with recurrent chest pain and ECG changes are more likely to develop complications whereas patients with recurrent chest pain without ECG changes are least likely to suffer i.e. are a low risk group. Moreover, NSTEMI patients develop more complications than STEMI patients and benefit from early invasive strategy. This is a simple risk stratification, however, further improvement can be made by bringing in non invasive workup for further risk stratification.
